Eli Lilly and Company

Eli Lilly and Company develops and markets pharmaceuticals worldwide for various conditions, including diabetes, type 2 diabetes, obesity, oncology products, rheumatoid arthritis, psoriasis, ulcerative colitis, depression, anxiety disorders, fibromyalgia, osteoporosis, and more. Its products include Basaglar, Humalog, Jardiance, Mounjaro, Trulicity, Zepbound, and others. The company also collaborates with other organizations. Founded in 1876, Lilly is headquartered in Indiana.

Overview

Sector

Pharmaceutical

Target Price

133.7 USD

Current Price

885.2 USD

Potential

-85%

Strengths

Strong EBITDA Margin of 43.11%.

Weaknesses

With a depreciation Potential of -84.89%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (55.94) is significantly higher than the sector mean (8.32).
EV/EBITDA (42.45) is significantly higher than the sector mean (21.51).
EV/EBIT (61.23) is significantly higher than the sector mean.
The Price to Free Cash Flow ratio (1916.26) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	75.0
EV/EBITDA	42.5
Price/Free Cash Flow'	1917.7
ROIC	18.4%
Net Debt/EBITDA	1.6